ARTV · Categories · Form 4

ARTV - SEC Form 4 insider transactions

Artiva Biotherapeutics Inc. (ARTV) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ARTV

• 47d
  Chief Financial Officer Huston Thad Allen was granted 220,000 shares (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 66d
  SEC Form 4 filed by Director Sorg Elaine K.

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 67d
  SVP, Research and Development Raymon Heather was granted 46,000 shares and covered exercise/tax liability with 1,521 shares, increasing direct ownership by 42% to 151,323 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 67d
  Chief Tech Operations Officer Horan Christopher was granted 117,300 shares and covered exercise/tax liability with 2,187 shares, increasing direct ownership by 62% to 300,452 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 67d
  COO, CLO, Secy, Compliance Off Bush Jennifer covered exercise/tax liability with 3,515 shares and was granted 117,300 shares, increasing direct ownership by 49% to 346,710 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 67d
  Chief Medical Officer Banerjee Subhashis was granted 102,000 shares, increasing direct ownership by 204% to 152,000 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 67d
  President and CEO Aslan Fred was granted 366,850 shares and covered exercise/tax liability with 14,600 shares, increasing direct ownership by 29% to 1,562,198 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 132d
  President and CEO Aslan Fred sold $19,122 worth of shares (3,187 units at $6.00), decreasing direct ownership by 0.26% to 1,209,948 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 135d
  SVP, Research and Development Raymon Heather was granted 67,253 shares, increasing direct ownership by 170% to 106,844 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 135d
  Chief Tech Operations Officer Horan Christopher was granted 107,156 shares, increasing direct ownership by 137% to 185,339 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 135d
  COO, CLO, Secy, Compliance Off Bush Jennifer was granted 84,877 shares, increasing direct ownership by 57% to 232,925 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 135d
  President and CEO Aslan Fred was granted 869,136 shares, increasing direct ownership by 253% to 1,213,135 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 160d
  SVP, Research and Development Raymon Heather covered exercise/tax liability with 1,375 shares, decreasing direct ownership by 3% to 39,591 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 160d
  Chief Tech Operations Officer Horan Christopher covered exercise/tax liability with 1,899 shares, decreasing direct ownership by 2% to 78,183 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 160d
  COO, CLO, Secy, Compliance Off Bush Jennifer covered exercise/tax liability with 3,055 shares, decreasing direct ownership by 2% to 148,048 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 160d
  Chief Financial Officer Krishnamohan Neha covered exercise/tax liability with 3,490 shares, decreasing direct ownership by 3% to 99,356 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 160d
  President and CEO Aslan Fred sold $21,522 worth of shares (6,375 units at $3.38) and covered exercise/tax liability with 6,347 shares, decreasing direct ownership by 4% to 343,999 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 191d
  President and CEO Aslan Fred sold $153,000 worth of shares (25,500 units at $6.00), decreasing direct ownership by 7% to 356,721 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 251d
  Chief Financial Officer Krishnamohan Neha covered exercise/tax liability with 7,154 shares, decreasing direct ownership by 7% to 102,846 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 251d
  President and CEO Aslan Fred covered exercise/tax liability with 8,944 shares and sold $69,579 worth of shares (25,500 units at $2.73), decreasing direct ownership by 8% to 382,221 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 251d
  SVP, Research and Development Raymon Heather covered exercise/tax liability with 2,384 shares, decreasing direct ownership by 5% to 40,966 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 251d
  Chief Tech Operations Officer Horan Christopher covered exercise/tax liability with 4,918 shares, decreasing direct ownership by 6% to 80,082 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 251d
  COO, CLO, Secy, Compliance Off Bush Jennifer covered exercise/tax liability with 8,346 shares, decreasing direct ownership by 5% to 151,103 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 304d
  SEC Form 4 filed by Director Ra Capital Management, L.P.

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 304d
  SEC Form 4 filed by Director Moore Alison

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 304d
  SEC Form 4 filed by Director Baker Daniel G.

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 304d
  SEC Form 4 filed by Director Stoppel Laura

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 304d
  SEC Form 4 filed by Director Daniels Brian

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 304d
  SEC Form 4 filed by Director Miralles Gines Diego

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 304d
  SEC Form 4 filed by Director Hougen Elizabeth L

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 366d
  Chief Medical Officer Banerjee Subhashis was granted 50,000 shares (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 415d
  President and CEO Aslan Fred was granted 200,000 shares, increasing direct ownership by 92% to 416,665 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 422d
  Chief Tech Operations Officer Horan Christopher was granted 60,000 shares, increasing direct ownership by 240% to 85,000 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 422d
  Chief Medical Officer Graef Thorsten was granted 60,000 shares, increasing direct ownership by 300% to 80,000 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 422d
  SVP, Research and Development Raymon Heather was granted 33,350 shares, increasing direct ownership by 334% to 43,350 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 422d
  Chief Financial Officer Krishnamohan Neha was granted 60,000 shares, increasing direct ownership by 120% to 110,000 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 422d
  COO, CLO, Secy, Compliance Off Bush Jennifer was granted 86,650 shares, increasing direct ownership by 119% to 159,449 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 452d
  SEC Form 4 filed by Director Baker Daniel G.

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 551d
  SEC Form 4 filed by Director Moore Alison

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 590d
  Chief Medical Officer Graef Thorsten was granted 20,000 shares (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 590d
  SVP, Research and Development Raymon Heather was granted 10,000 shares (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 590d
  Chief Tech Operations Officer Horan Christopher was granted 25,000 shares (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 590d
  Chief Financial Officer Krishnamohan Neha was granted 50,000 shares (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 590d
  COO, CLO, Secy, Compliance Off Bush Jennifer was granted 50,000 shares, increasing direct ownership by 219% to 72,799 units (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 643d
  Large owner Wellington Biomedical Innovation Master Investors (Cayman) I L.P. converted options into 145,089 shares and acquired $499,994 worth of shares (49,019 units at $10.20) (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
• 643d
  President and CEO Aslan Fred was granted 228,905 shares (SEC Form 4)

  4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

Other ARTV categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends